Litigation Details for Eagle Pharmaceuticals, Inc. v. Slayback Pharma LLC (D. Del. 2018)
✉ Email this page to a colleague
Eagle Pharmaceuticals, Inc. v. Slayback Pharma LLC (D. Del. 2018)
Docket | ⤷ Sign Up | Date Filed | 2018-12-11 |
Court | District Court, D. Delaware | Date Terminated | |
Cause | 35:271 Patent Infringement | Assigned To | |
Jury Demand | None | Referred To | |
Patents | 10,010,533; 9,265,831; 9,572,796; 9,572,797 | ||
Link to Docket | External link to docket |
Small Molecule Drugs cited in Eagle Pharmaceuticals, Inc. v. Slayback Pharma LLC
Details for Eagle Pharmaceuticals, Inc. v. Slayback Pharma LLC (D. Del. 2018)
Date Filed | Document No. | Description | Snippet | Link To Document |
---|---|---|---|---|
2019-05-09 | 31 | Opinion - Memorandum Opinion | the "#796 patent"), 9,572,797 (the "#797 patent"), and 10,010,533 (the "#533…equivalents of four patents: U.S. Patent Nos. 9,265,831 (the "#831 patent"), 9,572,796 …glycol in embodiments of the patented invention. See, e.g., #796 patent at 1 :60-64, 4:34-47, 5:27-35…;#533 patent"). See generally D.I. 1. Pending before me is Slayback's motion for judgment on…manufacture and sell before the four asserted patents expire a bendamustine drug that is bioequivalent | External link to document |
>Date Filed | >Document No. | >Description | >Snippet | >Link To Document |